Global Insomnia Treatment Market - 2023-2030

Overview

Global Insomnia Treatment Market reached US$ 3.7 billion in 2022 and is expected to reach US$ 5.1 billion by 2030 growing with a CAGR of 4.3% during the forecast period 2023-2030.

Insomnia is a sleep disorder that trouble falling asleep, staying asleep, and getting good quality sleep. Short-term insomnia is caused by stress or changes in the schedule or environment and this can last for a few days or weeks. Chronic or long-term insomnia occurs 3 or more nights a week or lasts more than 3 months.

The global insomnia treatment market has witnessed significant growth in recent years due to the intake of benzodiazepine drugs such as estazolam, temazepam, and quazepam. Temazepam is the most commonly prescribed benzodiazepine drug for insomnia. The choice of insomnia drug is based on the desired onset and duration of action.

Furthermore, significant growth drivers such as increasing stress levels, product launches, and rising research and developments give rise to future market growth. Significant key players like Merck & Co., Pfizer Inc., Abbott, Eisai Ltd., Idorsia Pharmaceuticals, and others are actively operating in the market.

Dynamics

Rising Stress Levels Among People is Expected to Boost the Market Growth

The rising stress levels among people across the globe act as a primary driver. Stress and anxiety often lead to insomnia and stressful life events or trauma are the main causes of sleeping disorders. Several psychological and physiological factors contribute to the onset and perpetuation of insomnia, such as anxious-ruminative personality traits, and stressful events.

For instance, According to the Health and Safety Executive report published in December 2021, over 822,000 workers suffered from work-related stress, depression, or anxiety in 2020-2021. Excessive occupational stress reported by the employees was 32.8%. More than half of respondents (51%) reported depressive symptoms and around 11% reported being diagnosed with insomnia.

Rising FDA Approvals for Insomnia Treatment is Expected to Boost the Market Growth

The increase in treatment approvals by regulatory bodies helps to drive market growth. The process of getting approval from the FDA generally involves preclinical experiments in an animal model of the disease. If the results of the animal model experiments are favorable then the FDA can approve the proposed structure of an interventional study.

For instance, in December 2022, Zydus Lifesciences Ltd received final approval from the US FDA to market its generic version of Triazolam tablets used on a short-term basis to treat insomnia. The medicine is used on a short-term basis to treat insomnia and difficulty falling asleep or staying asleep. It works by slowing activity in the brain to allow sleep.

Side Effects Associated with Insomnia Drugs

Over-the-counter prescription sleeping pills can cause constipation, dry mouth, headaches, and digestive problems. According to Cleveland Clinic, approximately 8 out of 10 people experience a hangover effect the day after taking sleep medicine. It leads to drowsiness, muddled thinking, and experience dizziness or balance problems.

These daytime effects can negatively impact the ability to drive, work, and complete daily tasks. Few prescription sleep medicines can bring on parasomnia and this disruptive sleep disorder can cause dangerous behaviors while the person is still mostly asleep. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

For more details on this report - Request for Sample

Segment Analysis

The global insomnia treatment market is segmented based on type, treatment, distribution channel and region.

Chronic Insomnia from the Type Segment Accounted for Approximately 47.3% of the Global Insomnia Treatment Market Share

The rising treatment drug approvals globally have contributed to the growing demand for the insomnia treatment market. For instance, in June 2023, Idorsia Ltd launched QUVIVIQ (daridorexant) in Switzerland which is a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning. QUVIVIQ is the first dual orexin receptor antagonist (DORA) available in Switzerland for the treatment of chronic insomnia disorder.

Additionally, in February 2021, Eisai Co., Ltd., its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with chronic insomnia which is characterized by difficulties with sleep onset or sleep maintenance.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America has maintained a significant proportion of the insomnia treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence of sleep disorders, organizations specific to insomnia, and research and developments in insomnia treatment.

For instance, according to the Sleep Foundation data published in 2023, it estimates around 50 million to 70 million people in the U.S. have ongoing sleep disorders. Approximately, 9% to 15% of U.S. adults have insomnia that affects their daytime activities. Among them, 40% of women are more likely to have insomnia than men.

Competitive Landscape

The major global players in the market include: Merck & Co., Pfizer Inc., Abbott, Genentech, LGM Pharma, Sigma Aldrich Sanofi S.A, Takeda Pharmaceuticals, Eisai Ltd., Idorsia Pharmaceuticals. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the insomnia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in insomnia treatment research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the insomnia treatment market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the insomnia treatment market is expected to be moderately affected over the forecast period.

By Type

• Acute Insomnia
• Chronic Insomnia.
• Onset Insomnia.
• Maintenance Insomnia.
• Behavioral Insomnia of Childhood

By Drugs

• Eszopiclone
• Ramelteon
• Zaleplon
• Zolpidem
• Estazolam
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2022, Pear Therapeutics received marketing authorization from the FDA for Somryst, its prescription digital therapeutic for adults with chronic insomnia. The treatment provides cognitive behavioral therapy for insomnia (CBTi) alongside personalized, algorithm-generated sleep restriction recommendations.
• In April 2022, Bukwang Pharmaceutical launched the Zaledeep Cap for the treatment of insomnia patients which is the first treatment in Korea that uses zaleplon as a main ingredient.

Why Purchase the Report?

• To visualize the global insomnia treatment market segmentation based on type, drugs, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global insomnia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global insomnia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies